Literature DB >> 27161788

Scope and frequency of fluconazole trailing assessed using EUCAST in invasive Candida spp. isolates.

Laura Judith Marcos-Zambrano1, Pilar Escribano2, Carlos Sánchez-Carrillo2, Emilio Bouza3, Jesús Guinea4.   

Abstract

Trailing is a well-known phenomenon that is defined as reduced but persistent visible growth of Candida spp. at fluconazole concentrations above the MIC. Trailing is commonly detected using the CLSI M27-A3 method, although little is known about its frequency when investigated with EUCAST. We assessed the frequency and scope of fluconazole trailing after using EUCAST EDef 7.2. against a large number of Candida spp. isolates from patients with candidemia. We studied 639 fluconazole-susceptible non-krusei Candida spp. isolates from 570 patients admitted to Gregorio Marañón Hospital. Isolates were tested in vitro for fluconazole susceptibility according to the EUCAST EDef 7.2 procedure; trailing was defined as the presence of any residual growth in wells containing fluconazole concentrations above the MIC. According to the mean percentage of trailing observed, isolates were classified as residual trailers (0.1-5%), slight trailers (6%-10%), moderate trailers (11%-15%), and heavy trailers (>15%). The relationship between trailing and genotyping was assessed. The mean overall percentage of trailing was 6.8%, with C. albicans and C. tropicalis showing the highest percentages (9.75% and 9.29%, respectively; P < .001). C. albicans and C. tropicalis had the highest percentage of heavy trailers (>15%). Trailing was not genotype-specific. Fluconazole trailing was observed frequently when EUCAST was used for antifungal susceptibility testing, particularly in isolates of C. albicans and C. tropicalis The cut-off proposed enabled us to classify the isolates according to the degree of trailing and can be used as the basis for future studies to evaluate the clinical impact of this phenomenon.
© The Author 2016. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Candida; EUCAST; Trailing; fluconazole

Mesh:

Substances:

Year:  2016        PMID: 27161788     DOI: 10.1093/mmy/myw033

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  10 in total

1.  The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant Candida albicans Isolates.

Authors:  Pilar Escribano; Laura Judith Marcos-Zambrano; Ana Gómez; Carlos Sánchez; M Carmen Martínez-Jiménez; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

2.  Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern.

Authors:  K M T Astvad; H K Johansen; B L Røder; F S Rosenvinge; J D Knudsen; L Lemming; H C Schønheyder; R K Hare; L Kristensen; L Nielsen; J B Gertsen; E Dzajic; M Pedersen; C Østergård; B Olesen; T S Søndergaard; M C Arendrup
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 3.  Drug resistance and tolerance in fungi.

Authors:  Judith Berman; Damian J Krysan
Journal:  Nat Rev Microbiol       Date:  2020-02-11       Impact factor: 60.633

4.  Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models.

Authors:  K M T Astvad; D Sanglard; E Delarze; R K Hare; M C Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Candida albicans and Candida dubliniensis Show Different Trailing Effect Patterns When Exposed to Echinocandins and Azoles.

Authors:  Rania Ayadi; Emilie Sitterlé; Christophe d'Enfert; Eric Dannaoui; Marie-Elisabeth Bougnoux
Journal:  Front Microbiol       Date:  2020-06-16       Impact factor: 5.640

6.  Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia.

Authors:  Alexander Rosenberg; Iuliana V Ene; Maayan Bibi; Shiri Zakin; Ella Shtifman Segal; Naomi Ziv; Alon M Dahan; Arnaldo Lopes Colombo; Richard J Bennett; Judith Berman
Journal:  Nat Commun       Date:  2018-06-25       Impact factor: 14.919

Review 7.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

8.  Minimal Inhibitory Concentration (MIC)-Phenomena in Candida albicans and Their Impact on the Diagnosis of Antifungal Resistance.

Authors:  Ulrike Binder; Maria Aigner; Brigitte Risslegger; Caroline Hörtnagl; Cornelia Lass-Flörl; Michaela Lackner
Journal:  J Fungi (Basel)       Date:  2019-09-04

9.  Novel ABC Transporter Associated with Fluconazole Resistance in Aging of Cryptococcus neoformans.

Authors:  Natalia Kronbauer Oliveira; Somanon Bhattacharya; Rina Gambhir; Manav Joshi; Bettina C Fries
Journal:  J Fungi (Basel)       Date:  2022-06-28

10.  Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata.

Authors:  Ewa Ksiezopolska; Miquel Àngel Schikora-Tamarit; Reinhard Beyer; Juan Carlos Nunez-Rodriguez; Christoph Schüller; Toni Gabaldón
Journal:  Curr Biol       Date:  2021-10-25       Impact factor: 10.834

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.